Outlook Therapeutics (OTLK) Stock Forecast, Price Target & Predictions

OverviewOwnership Financials Chart Transcripts

OTLK Stock Forecast

Outlook Therapeutics stock forecast is as follows: a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

OTLK Analyst Ratings

Buy

According to 5 Wall Street analysts, Outlook Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for OTLK stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 29, 2024	H.C. Wainwright	Buy	Buy	Hold
Nov 29, 2024	BTIG	Buy	Buy	Hold
May 17, 2024	H.C. Wainwright	Buy	Buy	Hold
Mar 27, 2024	BTIG		Buy	Upgrade
Jan 25, 2024	Guggenheim		Buy	Upgrade
Jan 25, 2024	Brookline Capital		Buy	Upgrade
Dec 29, 2023	Ascendiant	Buy	Buy	Hold
Nov 03, 2023	H.C. Wainwright		Buy	Upgrade

Outlook Therapeutics's last stock rating was published by H.C. Wainwright on Nov 29, 2024. The company gave OTLK a "Buy" rating, the same as its previous rate.

Outlook Therapeutics Financial Forecast

Outlook Therapeutics Revenue Forecast

	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 23	Sep 21	Jun 21	Mar 21	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Jun 17	Dec 16
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$5.85M	$583.85K	$641.14K	$771.89K	$303.14K	$303.14K
Avg Forecast	$5.12M	$2.25M	$702.60K	$200.00K	$237.67K	-	$2.49M	$300.00K	$325.00K	$325.00K	$162.50K	$216.67K	$162.50K	$333.33K	$637.50K	$683.33K	$750.00K	$553.44K	$872.73K	$235.54K
High Forecast	$5.12M	$2.25M	$702.60K	$200.00K	$237.67K	-	$2.49M	$300.00K	$325.00K	$325.00K	$162.50K	$216.67K	$162.50K	$333.33K	$637.50K	$683.33K	$750.00K	$664.12K	$1.05M	$282.65K
Low Forecast	$5.12M	$2.25M	$702.60K	$200.00K	$237.67K	-	$2.49M	$300.00K	$325.00K	$325.00K	$162.50K	$216.67K	$162.50K	$333.33K	$637.50K	$683.33K	$750.00K	$442.75K	$698.18K	$188.43K
# Analysts	1	1	1	4	1	-	4	2	2	2	4	5	4	4	3	4	3	8	13	16
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9.18%	0.85%	0.85%	1.39%	0.35%	1.29%

Outlook Therapeutics's average Quarter revenue forecast for Dec 19 based on 4 analysts is $333.33K, with a low forecast of $333.33K, and a high forecast of $333.33K. OTLK's average Quarter revenue forecast represents a -94.31% decrease compared to the company's last Quarter revenue of $5.85M (Sep 19).

Outlook Therapeutics EBITDA Forecast

	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 23	Sep 21	Jun 21	Mar 21	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Jun 17	Dec 16
# Analysts	1	1	1	4	1	-	4	2	2	2	4	5	4	4	3	4	3	8	13	16
EBITDA	-	-	-	-	-	-	$-56.84T	$-52.18M	$-11.89M	$-12.77M	$-9.82M	$-5.72M	$-4.83M	$-15.83M	$-11.63M	$-3.30M	$-8.37M	$-5.89M	$-3.02M	$-18.04M
Avg Forecast	$3.07M	$1.35M	$421.56K	$120.00K	$142.60K	-	$1.49M	$180.00K	$195.00K	$-10.98M	$97.50K	$130.00K	$-2.71M	$200.00K	$382.50K	$410.00K	$-9.39M	$-3.58M	$-4.50M	$-12.86M
High Forecast	$3.07M	$1.35M	$421.56K	$120.00K	$142.60K	-	$1.49M	$180.00K	$195.00K	$-8.78M	$97.50K	$130.00K	$-2.17M	$200.00K	$382.50K	$410.00K	$-7.51M	$-2.87M	$-3.60M	$-10.29M
Low Forecast	$3.07M	$1.35M	$421.56K	$120.00K	$142.60K	-	$1.49M	$180.00K	$195.00K	$-13.17M	$97.50K	$130.00K	$-3.25M	$200.00K	$382.50K	$410.00K	$-11.27M	$-4.30M	$-5.40M	$-15.43M
Surprise %	-	-	-	-	-	-	-38087260.87%	-289.87%	-60.98%	1.16%	-100.75%	-44.00%	1.78%	-79.15%	-30.41%	-8.06%	0.89%	1.64%	0.67%	1.40%

undefined analysts predict OTLK's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Outlook Therapeutics's previous annual EBITDA (undefined) of $NaN.

Outlook Therapeutics Net Income Forecast

	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 23	Sep 21	Jun 21	Mar 21	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Jun 17	Dec 16
# Analysts	1	1	1	4	1	-	4	2	2	2	4	5	4	4	3	4	3	8	13	16
Net Income	-	-	-	-	-	-	$-58.98T	$-53.16M	$-12.20M	$-13.11M	$-9.92M	$-3.01M	$-5.70M	$-16.60M	$-10.10M	$-4.44M	$-10.24M	$-7.54M	$-5.33M	$-19.10M
Avg Forecast	$-12.08M	$-15.03M	$-17.99M	$-22.52M	$-20.47M	$-26.31M	$-29.30M	$-32.27M	$-35.67M	$-11.47M	$-47.90M	$-48.41M	$-2.51M	$-112.10M	$-157.95M	$-185.13M	$-11.49M	$-4.59M	$-7.94M	$-13.62M
High Forecast	$-12.08M	$-15.03M	$-17.99M	$-22.52M	$-18.74M	$-26.31M	$-24.41M	$-32.27M	$-35.67M	$-9.17M	$-47.90M	$-48.41M	$-2.01M	$-112.10M	$-157.95M	$-185.13M	$-9.19M	$-3.67M	$-6.35M	$-10.89M
Low Forecast	$-12.08M	$-15.03M	$-17.99M	$-22.52M	$-21.95M	$-26.31M	$-39.06M	$-32.27M	$-35.67M	$-13.76M	$-47.90M	$-48.41M	$-3.01M	$-112.10M	$-157.95M	$-185.13M	$-13.78M	$-5.51M	$-9.53M	$-16.34M
Surprise %	-	-	-	-	-	-	2013202.69%	1.65%	0.34%	1.14%	0.21%	0.06%	2.27%	0.15%	0.06%	0.02%	0.89%	1.64%	0.67%	1.40%

Outlook Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. OTLK's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Outlook Therapeutics SG&A Forecast

	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 23	Sep 21	Jun 21	Mar 21	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Jun 17	Dec 16
# Analysts	1	1	1	4	1	-	4	2	2	2	4	5	4	4	3	4	3	8	13	16
SG&A	-	-	-	-	-	-	$26.67T	$12.77M	$2.93M	$4.10M	$2.39M	$3.29M	$1.96M	$2.34M	$2.78M	$1.83M	$1.85M	$2.45M	$3.50M	$4.89M
Avg Forecast	$4.79M	$2.10M	$657.35K	$187.12K	$222.36K	-	$2.33M	$280.68K	$304.07K	$304.07K	$152.03K	$202.71K	$152.03K	$311.86K	$596.44K	$639.32K	$701.70K	$517.79K	$816.52K	$220.37K
High Forecast	$4.79M	$2.10M	$657.35K	$187.12K	$222.36K	-	$2.33M	$280.68K	$304.07K	$304.07K	$152.03K	$202.71K	$152.03K	$311.86K	$596.44K	$639.32K	$701.70K	$621.35K	$979.82K	$264.44K
Low Forecast	$4.79M	$2.10M	$657.35K	$187.12K	$222.36K	-	$2.33M	$280.68K	$304.07K	$304.07K	$152.03K	$202.71K	$152.03K	$311.86K	$596.44K	$639.32K	$701.70K	$414.23K	$653.21K	$176.30K
Surprise %	-	-	-	-	-	-	11462795.53%	45.49%	9.64%	13.47%	15.72%	16.21%	12.87%	7.49%	4.66%	2.87%	2.64%	4.72%	4.29%	22.18%

Outlook Therapeutics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to OTLK last annual SG&A of $26.67T (Sep 23).

Outlook Therapeutics EPS Forecast

	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 23	Sep 21	Jun 21	Mar 21	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Jun 17	Dec 16
# Analysts	1	1	1	4	1	-	4	2	2	2	4	5	4	4	3	4	3	8	13	16
EPS	-	-	-	-	-	-	$-0.24	$-0.32	$-0.07	$-0.09	$-0.11	$-0.03	$-0.12	$-0.62	$-0.34	$-0.20	$-0.98	$-2.64	$-1.76	$-6.56
Avg Forecast	$-0.47	$-0.59	$-0.71	$-0.88	$-0.80	$-1.03	$-1.15	$-1.27	$-1.40	$-1.93	$-1.88	$-1.90	$-2.88	$-4.40	$-6.20	$-7.27	$-13.20	$-1.12	$-7.63	$-0.31
High Forecast	$-0.47	$-0.59	$-0.71	$-0.88	$-0.74	$-1.03	$-0.96	$-1.27	$-1.40	$-1.93	$-1.88	$-1.90	$-2.88	$-4.40	$-6.20	$-7.27	$-13.20	$-0.90	$-6.11	$-0.25
Low Forecast	$-0.47	$-0.59	$-0.71	$-0.88	$-0.86	$-1.03	$-1.53	$-1.27	$-1.40	$-1.93	$-1.88	$-1.90	$-2.88	$-4.40	$-6.20	$-7.27	$-13.20	$-1.34	$-9.16	$-0.37
Surprise %	-	-	-	-	-	-	0.21%	0.25%	0.05%	0.05%	0.06%	0.02%	0.04%	0.14%	0.05%	0.03%	0.07%	2.36%	0.23%	21.16%

According to undefined Wall Street analysts, Outlook Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to OTLK previous annual EPS of $NaN (undefined).

Outlook Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
RVPH	Reviva Pharmaceuticals	$1.40	$10.00	614.29%	Buy
OTLK	Outlook Therapeutics	$1.44	$10.00	594.44%	Buy
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
CKPT	Checkpoint Therapeutics	$3.72	$20.00	437.63%	Buy
XFOR	X4 Pharmaceuticals	$0.74	$3.67	395.95%	Buy
HRTX	Heron Therapeutics	$1.65	$7.00	324.24%	Buy
SLS	SELLAS Life Sciences Group	$0.88	$2.80	218.18%	Buy
TERN	Terns Pharmaceuticals	$6.80	$18.67	174.56%	Buy
EYPT	EyePoint Pharmaceuticals	$8.02	$22.00	174.31%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
HOOK	HOOKIPA Pharma	$2.13	$3.00	40.85%	Buy
KOD	Kodiak Sciences	$8.87	$11.00	24.01%	Buy
CDTX	Cidara Therapeutics	$22.81	$12.00	-47.39%	Buy

OTLK Forecast FAQ

Is Outlook Therapeutics a good buy?

Yes, according to 5 Wall Street analysts, Outlook Therapeutics (OTLK) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of OTLK's total ratings.

What are Outlook Therapeutics's analysts' financial forecasts?

Outlook Therapeutics's analysts financial forecasts for the fiscal year (Sep 2024) are as follows: average revenue is $237.67K (high $237.67K, low $237.67K), average EBITDA is $142.6K (high $142.6K, low $142.6K), average net income is $-46.78M (high $-45.054M, low $-48.259M), average SG&A $222.36K (high $222.36K, low $222.36K), and average EPS is $-1.836 (high $-1.768, low $-1.894). OTLK's analysts financial forecasts for the fiscal year (Sep 2025) are as follows: average revenue is $8.27M (high $8.27M, low $8.27M), average EBITDA is $4.96M (high $4.96M, low $4.96M), average net income is $-67.614M (high $-67.614M, low $-67.614M), average SG&A $7.74M (high $7.74M, low $7.74M), and average EPS is $-2.654 (high $-2.654, low $-2.654).

Did the OTLK's actual financial results beat the analysts' financial forecasts?

Based on Outlook Therapeutics's last annual report (Sep 2019), the company's revenue was $8.15M, beating the average analysts forecast of $2.07M by 293.37%. Apple's EBITDA was $-21.667M, beating the average prediction of $-8.597M by 152.03%. The company's net income was $-34.524M, missing the average estimation of $-355M by -90.26%. Apple's SG&A was $9.37M, beating the average forecast of $1.94M by 383.61%. Lastly, the company's EPS was $-1.9, missing the average prediction of $-26.667 by -92.88%. In terms of the last quarterly report (Sep 2019), Outlook Therapeutics's revenue was $5.85M, beating the average analysts' forecast of $637.5K by 818.20%. The company's EBITDA was $-11.631M, missing the average prediction of $382.5K by -3140.71%. Outlook Therapeutics's net income was $-10.096M, missing the average estimation of $-158M by -93.61%. The company's SG&A was $2.78M, beating the average forecast of $596.44K by 366.46%. Lastly, the company's EPS was $-0.338, missing the average prediction of $-6.2 by -94.55%